Cheryl E Gillett
Overview
Explore the profile of Cheryl E Gillett including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
834
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Anstee J, Feehan K, Opzoomer J, Dean I, Muller H, Bahri M, et al.
Dev Cell
. 2023 Jul;
58(17):1548-1561.e10.
PMID: 37442140
Tumor-associated macrophages (TAMs) are a heterogeneous population of cells that facilitate cancer progression. However, our knowledge of the niches of individual TAM subsets and their development and function remain incomplete....
2.
Kosti P, Opzoomer J, Larios-Martinez K, Henley-Smith R, Scudamore C, Okesola M, et al.
Cell Rep Med
. 2021 May;
2(4):100227.
PMID: 33948568
Utilizing T cells expressing chimeric antigen receptors (CARs) to identify and attack solid tumors has proven challenging, in large part because of the lack of tumor-specific targets to direct CAR...
3.
Muliaditan T, Caron J, Okesola M, Opzoomer J, Kosti P, Georgouli M, et al.
Nat Commun
. 2018 Jul;
9(1):2951.
PMID: 30054470
Tumour-associated macrophages (TAMs) play an important role in tumour progression, which is facilitated by their ability to respond to environmental cues. Here we report, using murine models of breast cancer,...
4.
Grigoriadis A, Gazinska P, Pai T, Irhsad S, Wu Y, Millis R, et al.
J Pathol Clin Res
. 2018 Feb;
4(1):39-54.
PMID: 29416876
The prognostic importance of lymph node (LN) status and tumour-infiltrating lymphocytes (TILs), is well established, particularly TILs in triple negative breast cancers (TNBCs). So far, few studies have interrogated changes...
5.
Muliaditan T, Opzoomer J, Caron J, Okesola M, Kosti P, Lall S, et al.
Clin Cancer Res
. 2018 Jan;
24(7):1617-1628.
PMID: 29339440
Unprecedented clinical outcomes have been achieved in a variety of cancers by targeting immune checkpoint molecules. This preclinical study investigates heme oxygenase-1 (HO-1), an immunosuppressive enzyme that is expressed in...
6.
Lawler K, Papouli E, Naceur-Lombardelli C, Mera A, Ougham K, Tutt A, et al.
Breast Cancer Res
. 2017 Oct;
19(1):113.
PMID: 29029636
Background: Metastases from primary breast cancers can involve single or multiple organs at metastatic disease diagnosis. Molecular risk factors for particular patterns of metastastic spread in a clinical population are...
7.
Irshad S, Flores-Borja F, Lawler K, Monypenny J, Evans R, Male V, et al.
Cancer Res
. 2017 Jan;
77(5):1083-1096.
PMID: 28082403
Cancer cells tend to metastasize first to tumor-draining lymph nodes, but the mechanisms mediating cancer cell invasion into the lymphatic vasculature remain little understood. Here, we show that in the...
8.
Joshi S, Watkins J, Gazinska P, Brown J, Gillett C, Grigoriadis A, et al.
BMC Cancer
. 2015 Jul;
15:546.
PMID: 26205655
Background: Immunohistochemical assessment of proliferation may provide additional prognostic information in early breast cancer. However, due to a lack of methodological standards proliferation markers are still not routinely used for...
9.
Weitsman G, Lawler K, Kelleher M, Barrett J, Barber P, Shamil E, et al.
Biochem Soc Trans
. 2014 Nov;
42(6):1498-505.
PMID: 25399560
Breast cancer heterogeneity demands that prognostic models must be biologically driven and recent clinical evidence indicates that future prognostic signatures need evaluation in the context of early compared with late...
10.
The ErbB4 CYT2 variant protects EGFR from ligand-induced degradation to enhance cancer cell motility
Kiuchi T, Ortiz-Zapater E, Monypenny J, Matthews D, Nguyen L, Barbeau J, et al.
Sci Signal
. 2014 Aug;
7(339):ra78.
PMID: 25140053
The epidermal growth factor receptor (EGFR) is a member of the ErbB family that can promote the migration and proliferation of breast cancer cells. Therapies that target EGFR can promote...